| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.29 | 2e-10 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.21 | 3e-07 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | 0.34 | 2e-06 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.31 | 3e-06 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.3 | 3e-06 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.37 | 4e-06 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.19 | 7e-06 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.29 | 8e-06 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.29 | 1e-05 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.21 | 2e-05 |